Sabon Dan takarar Drug don cututtukan ƙwayoyin cuta masu jure wa Carbapenem

Sumitovant Biopharma Ltd., tare da haɗin gwiwar kamfanin iyaye Sumitomo Dainippon Pharma Co., Ltd., kwanan nan ya sanar da ƙaddamar da wani binciken lokaci na 1 a Amurka game da sabon dan takarar magani ("KSP-1007") don cututtukan ƙwayoyin cuta na carbapenem. . Ƙaddamarwar ta samo asali ne sakamakon wani aikin bincike na haɗin gwiwa tsakanin Sumitomo Dainippon Pharma da Cibiyar Kitasato a Japan. Sumitovant yana jagorantar shirin na fili a cikin Amurka wanda ke yin niyya mai rikitarwa na urinary fili da cututtukan ciki-ciki.            

Myrtle Potter, Babban Jami'in Sumitovant ya ce "Akwai babban bukatar likita da ba a biya ba don ingantattun hanyoyin magance cututtuka masu rikitarwa a fadin duniya." “Haɓaka novel maganin kashe ƙwayoyin cuta bai taɓa zama mafi mahimmanci ko gaggawa ba. Na yi imanin wannan ɗan takarar magani yana da yuwuwar zama ingantaccen zaɓi na magani akan cututtukan ƙwayoyin cuta masu jure wa carbapenem waɗanda ke shafar mutane da yawa a cikin Amurka da ƙari. ”

Cutar cututtuka na tsarin fitsari na daga cikin abubuwan da ke haifar da sepsis. Cututtuka masu rikitarwa sune waɗanda ke da haɗarin gazawar jiyya kuma galibi suna buƙatar darussan ƙwayoyin cuta masu tsayi. Cututtukan cikin ciki masu rikitarwa sune cututtuka waɗanda suka wuce bangon wani ɗan ƙaramin vicus na asali zuwa cikin rami na ciki yayin da ake danganta su da ƙura ko peritonitis.

"Ya bayyana daga bayanan da ba na asibiti ba cewa KSP-1007 a fili da karfi yana hana β-lactamases, wanda shine enzymes da aka samar da kwayoyin cutar da za su iya lalata maganin rigakafi na carbapenem," in ji Salomon Azoulay, Babban Jami'in Kiwon Lafiyar MD da Shugaban Bincike & Ci gaba a Sumitovant, wanda ƙungiyarsa ke jagorantar ƙira da aiwatar da binciken lokaci na 1 a cikin Amurka "Muna nazarin KSP-1007 a hade tare da meropenem hydrate, maganin rigakafi na carbapenem, wanda aka riga aka yi amfani dashi don magance cututtukan Gram (-), don haɓaka inganci a cikin rikitarwa. cututtuka na urinary tract da intra-abdominal infections."

Sabbin ci gaban ƙwayoyin cuta wani lamari ne na gaggawa na duniya. Fitowa da yaɗuwar ƙwayoyin cuta na ƙwayoyin cuta (AMR), waɗanda ke da juriya ga maganin rigakafi, matsala ce da ke daɗa girma a duniya. Bankin Duniya ya yi kiyasin cewa mutane 700,000 ne ke mutuwa sakamakon kamuwa da cutar AMR a kowace shekara.1 Hukumar Lafiya ta Duniya ta yi kira da a dauki matakan gaggawa a matakin kasa da na duniya don yakar wadannan cututtuka da samar da sabbin magunguna. Saboda karuwar amfani da maganin rigakafi da ke da alaƙa da COVID-19, akwai damuwa cewa ƙwayoyin cuta masu jurewa za su bazu har ma da gaba.

Sumitovant da Sumitomo Dainippon Pharma sun himmatu wajen nemo sabbin zaɓuɓɓukan jiyya don mafi ƙalubalanci jiyya da yanayi a duk faɗin duniya. Ƙirƙirar sabbin magungunan kashe ƙwayoyin cuta wani yanki ne da aka mayar da hankali ga masu binciken kamfanoni.